大拱桥--暨南大学学生门户 » 图书馆 » 免疫疗法 » Cancer vaccines : sixth international symposium
名称 Cancer vaccines : sixth international symposium
索引号 R730.51-532/E20101
分类号 R730.51-532
R730.51(免疫疗法)
R730.5(肿瘤治疗学)
R730(一般性问题)
R73(肿瘤学)
R(医药,卫生)
作者 International Cancer Vaccine Symposium (6th : 2008 : New York、 N.Y.)、Steinman、 Ralph.、Banchereau、 Jacques.、Finn、 Olivera J.、
出版社 Boston, MA : Published by Blackwell Pub. on behalf of the New York Academy of Sciences, c2009.
ISBN
页数 vi, 121 p. : ill. ; 26 cm.
价格
标签
简介
注解 "This volume presents manuscripts stemming from the conference "Sixth International Cancer Vaccine Symposium: Stages of Cancer Vaccine Development," held at the New York Academy of Sciences Conference Center on Oct. 28-30, 2008."--P. v. 附註 Includes bibliographical references. 內容 Some scientific and organizational challenges in cancer immunology -- The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells -- Brain tumor immunotherapy with type-1 polarizing strategies -- Harnessing human dendritic cell subsets to design novel vaccines -- Dendritic cell-based vaccines for pancreatic cancer and melanoma -- Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers -- Witch hunt against tumor cells enhanced by dendritic cells -- Harnessing CD1D-restricted t cells toward antitumor immunity in humans -- Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53-/- mice -- Targets of protective tumor immunity -- Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer -- Harnessing dendritic cells to generate cancer vaccines -- Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells -- Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model -- Hematopoietic stem and progenitor cells and the inflammatory response.